Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab have?
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab has 380 citations in the OpenAlex counts ScholarIQ stores.
When was Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab published?
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab has 2017 year in the ScholarIQ index.
What is the open-access status of Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab?
Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab has hybrid oa status in the ScholarIQ index.
What is the DOI of Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab?
The DOI for Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab is on the source record.
What is the PMID of Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab?
The PMID for Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab is on the source record.
What is the OpenAlex record for Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab?
The OpenAlex for Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab is on the source record.